Class / Patent application number | Description | Number of patent applications / Date published |
514635000 | Biguanides (i.e., N=C(-N)-N(N-)C=N) | 85 |
20080255241 | Self-Sterilized, Antiseptic Collagen Preparations, Their Use and Methods For Producing Them - A method is provided for sterilizing a collagen preparation and for production of self-sterilized, antiseptic collagen preparations. The preparations may be used for producing collagen products, such as sponges, films or gels, especially for medical and/or cosmetic purposes. | 10-16-2008 |
20090069436 | ANTIMICROBIAL SKIN COMPOSITION COMPRISING A BIGUANIDE OR A QUATERNIUM COMPOUND - An antimicrobial skin treatment composition comprises 0.001-5% w/w of a biguanide compound and/or 0.001-5% w/w of a quaternary ammonium compound. The composition may be a skin rub, in which case it may additionally comprise at least one alcohol, at least one lipogel and at least one oil. Alternatively the composition may be a skin wash, in which case it may additionally comprise at least one detergent agent and at least one amphoteric surfactant. | 03-12-2009 |
20090069437 | Compositions for Oral Transmucosal Delivery of Metformin - The invention relates to oral transmucosal pharmaceutical compositions comprising metformin or a pharmaceutically acceptable salt thereof, methods of using the compositions to treat various conditions, including diabetes, methods of preparing the compositions, and preparations for use in making the compositions. | 03-12-2009 |
20090124702 | Pharmaceutical Compositions of Metformin - The present invention relates to an extended release dosage form of highly water-soluble antidiabetic drug metformin or its pharmaceutically acceptable salts. This invention also relates to methods for preparing the extended release dosage forms of metformin or its pharmaceutically acceptable salts. | 05-14-2009 |
20090163598 | ANTIMICROBIAL CELLULOSE SPONGE AND METHOD OF MAKING - Biguanide bonded within a cellulose sponge inhibits or prevents the growth of microorganisms such as bacteria, mold, and fungus within the cellulose sponge over the useful life of the cellulose sponge. | 06-25-2009 |
20090186943 | Antiseptic Ointment - Disclosed is a microbicidal and antiseptic ointment which contains at least one kind selected from the group consisting of chlorhexidine and its salt in an amount from 0.1 to 4 mass % and a hydrocarbon alcohol having 2 to 3 carbon atoms in an amount from 8 to 25 mass %, and sustains a microbicidal effect for at least 6 hours that is approved by a test method for evaluation of hand antisepsis. | 07-23-2009 |
20100022654 | ANTIMICROBIAL COMPOSITIONS - Antimicrobial compositions are provided that include a hydroalcoholic solvent system comprising a lower C | 01-28-2010 |
20100029779 | COMPOSITION AND METHOD FOR TREATMENT OF MRSA - The present invention provides a photosensitizing composition for treatment of MRSA comprising a photosensitizer and chlorhexidine and a pharmaceutically acceptable carrier. The present invention also provides a method for reducing disease causing microbes comprising: applying the composition comprising a photosensitizer, chlorhexidine at a concentration of more than about 0.01% and less than about 2% v/v, and a pharmaceutically acceptable carrier to a treatment site; and applying light to the treatment site at a wavelength absorbed by the photosensitizer so as to reduce the microbes at the treatment site. | 02-04-2010 |
20100029780 | TOPICAL COMPOSITION - A topical composition comprising at least one C | 02-04-2010 |
20100035997 | KIT FOR APPLYING A POLYMERIZABLE ADHESIVE COMPOSITION TO TISSUES - The invention relates to a kit for the topical and/or internal application of a polymerisable adhesive composition to tissues, enabling improved control of the polymerisation speed on the surface of the tissue, in addition to the effective disinfection of the wound. The kit consists of at least one receptacle and contains a polymerisable adhesive composition based on cyanacrylate, in addition to a disinfectant composition. | 02-11-2010 |
20100069502 | Assay - The invention relates to a method for identifying a candidate agent for use in a medicament for diabetes or obesity said method comprising (i) providing a candidate inhibitor of PPM phosphatase, (ii) providing a first and a second sample comprising PPM phosphatase, (iii) contacting said candidate inhibitor with said first sample comprising PPM phosphatase, and (iv) assaying said first and second samples for PPM phosphatase activity, wherein said PPM phosphatase is selected from the group consisting of PPM1E, PPM1F, PPM1J, PPM1K, PPM1L and PPM1M, wherein if the PPM phosphatase activity is lower in said first sample than in said second sample then said candidate inhibitor is identified as a candidate agent for use in a medicament for diabetes or obesity, preferably type II diabetes. The invention also relates to the use of metformin and phenformin as inhibitors of PPM phosphatases. | 03-18-2010 |
20100087544 | N, N -DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same. | 04-08-2010 |
20100113603 | COMBINATION THERAPIES FOR THE TREATMENT OF OBESITY - Described are pharmaceutical compositions comprising bupropion, metformin, phentermine, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of bupropion, metformin, and phentermine. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 05-06-2010 |
20100113604 | COMBINATION THERAPIES FOR THE TREATMENT OF OBESITY - Described are pharmaceutical compositions comprising metformin, diethylpropion, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of metformin and diethylpropion. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 05-06-2010 |
20100125105 | ANTIMICROBIAL DEVICE AND MATERIALS FOR FLUID TREATMENT - Compositions comprising miscible blends of antimicrobial bisguanide compounds with certain thermoplastic polymers are provided. These antimicrobial polymeric materials may be further processed into particulate or fiber form for use in fluid treatment devices and processes. The antimicrobial bisguanide compound, such as chlorhexidine, is distributed at the molecular level within at least one thermoplastic polymer, such as a polyolefin, in which the antimicrobial bisguanide compound is soluble to form a miscible blend, which may be from about 1% to about 25% by weight antimicrobial bisguanide compound. The antimicrobial polymeric materials may be secured in a device for antimicrobial treatment of a fluid. The devices may comprise a housing having at least one inlet orifice and at least one outlet orifice, the antimicrobial polymeric material being secured within the house and configured to contact a fluid flowing through the housing between the inlet orifice and the outlet orifice. | 05-20-2010 |
20100216889 | PROLONGED EFFECT DISINFECTANT CLEANSER - The present invention relates to cleanser compositions, and their uses, wherein the cleanser compositions comprise one or more cationic antiseptic agents, a film-forming cationic emulsifying agent, a dispersing auxiliary solvent, a solvent system, and optionally an alkanediol. | 08-26-2010 |
20100240762 | SANITIZER FORMULATIONS - The present invention relates to a stable and effective sanitizer formulation for indirect food contact applications. The formulation contains: (a) an antimicrobial active agent selected from the group consisting of biguanides, monoguanides, and combinations thereof; (b) a dialkyldimethyl ammonium salt, and (c) a compound selected from the group consisting of an alkyldimethylbenzyl ammonium salt, an alkyldimethyl(ethylbenzyl) ammonium salt, an alkoxylated alcohol, and combinations thereof. | 09-23-2010 |
20100249241 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - Disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as a preparation method thereof and a pharmaceutical composition comprising the same. | 09-30-2010 |
20100292338 | SILK MEDICAL DEVICE WITH ANTIMICROBIAL PROPERTIES AND A METHOD OF MANUFACTURE THEREOF - A silk medical device is described, which is useful for the treatment of wounds to prevent infection. The silk medical device is manufactured from a silk protein material that is loaded with a polymeric cationic antimicrobial, such as polyhexamethylene biguanide (PHMB). | 11-18-2010 |
20100305211 | Gentle-Acting Skin-Disinfectants and Hydroalcoholic Gel Formulations - Antimicrobial compositions having synergistic combinations of octoxyglycerin and at least one other antimicrobial agent in formulations which are more effective than prior art compositions without causing increased irritation to the skin of the average user. In certain embodiments, skin irritation may be minimized by low concentrations of antimicrobials and/or the presence of soothing compounds such as zinc. Preferred embodiments include combinations of octoxyglycerin, a quaternary compound, and at least one other antimicrobial agent. Without being bound to any particular theory, it is hypothesized that the unexpected antimicrobial effectiveness of combinations of octoxyglycerin may result from an enhancement of the permeability of microbes to antimicrobials caused by octoxyglycerin. Hydroalcoholic gel composition containing alcohol, water, hydrogel, and emollient or emulsifier, wherein the composition has a viscosity of below 2000 centipoises at between 20 and 40° C. This skin-friendly hydroalcoholic gel composition, which can be further combined with silicone polymer, emollient solvent, thickening agent and antimicrobial agent, enhances rapid and long-term antimicrobial efficacy. | 12-02-2010 |
20100331419 | Combination Therapies for the Treatment of Obesity - Described are pharmaceutical compositions comprising bupropion, metformin, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of bupropion and metformin. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 12-30-2010 |
20100331420 | Combination Therapies for the Treatment of Obesity - Described are pharmaceutical compositions comprising sibutramine, metformin, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of sibutramine and metformin. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 12-30-2010 |
20100331421 | DISINFECTANT AND/OR BACTERICIDAL AQUEOUS COMPOSITIONS - The present invention provides a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt and and a cyclodextrin. | 12-30-2010 |
20100331422 | STABLE HYDROALCOHOLIC COMPOSITIONS - A hydroalcoholic lotion is disclosed which comprises (a) a lower alcohol and water in a weight ratio of about 35:65 to 100:0, and (b) between at least 0.5% and 8% by weight thickener system comprised of at least one emulsifier present in at least 0.05% by weight wherein the composition in a polymer free state has a viscosity of at least 4,000 centipoise at 23 degrees C. and wherein the emulsifier is comprised of at least one hydrophobic group and at least one hydrophilic group. The hydroalcoholic composition is useful as a hand preparation such as a lotion or as a presurgical scrub replacement. | 12-30-2010 |
20100331423 | AQUEOUS SOLUTION OF OLANEXIDINE, METHOD OF PREPARING THE AQUEOUS SOLUTION, AND DISINFECTANT - The present invention provides a disinfectant that contains olanexidine in a concentration sufficient to exhibit an effective bactericidal effect, and that has hardly any side effects such as skin irritation. Specifically, the present invention provides a disinfectant containing an aqueous solution that contains olanexidine and at least an equimolar amount of gluconic acid, and substantially contains neither an acid other than gluconic acid nor a salt of the acid other than gluconic acid. | 12-30-2010 |
20110021634 | PROCESSES FOR PREPARING METFORMIN HYDROCHLORIDE - A process for reducing dimethylamine content in metformin hydrochloride is disclosed. The process comprises:
| 01-27-2011 |
20110054036 | COMPOSITION AND METHOD FOR IRRIGATION OF A PREPARED DENTAL ROOT CANAL - Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediamine tetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection. | 03-03-2011 |
20110207826 | LACTOSE AND CELLULOSE-BASED TABLETING AID - The present invention concerns a process for producing a granulate based on lactose and cellulose (derivative), a granulate obtainable by the process and its use as a tabletting excipient. | 08-25-2011 |
20110251285 | COMBINATIONS OF PRESERVATIVES FOR OPHTHALMIC COMPOSITIONS - The present invention provides a preservative composition for protecting ophthalmic solutions from microbial attack comprising a combination of benzalkonium ion and polyhexamethylene biguanide (PHMB) wherein the combined concentrations of benzalkonium ion and polyhexamethylene biguanide (PHMB) in said composition is sufficient to provide protection against microbial attack when said composition is added to an ophtalmic solution as compared to said ophthalmic soulution having the same concentration of benzalkonium ion and polyhexamethylene biguanide (PHMB), alone. | 10-13-2011 |
20110263717 | Ophthalmic Compositions with Biguanide and PEG-Glycerol Esters - Ophthalmic compositions that comprise 0.1 ppm to 2 ppm of poly(hexamethylene biguanide); and 0.005 wt. % to 0.3 wt. % of a PEG-glycerol ester of general formula I | 10-27-2011 |
20120041069 | SGLT2 INHIBITOR DOSAGE FORMS - A pharmaceutical composition comprising a sodium-dependent glucose transporter (SGLT2) inhibitor and a biguanide, wherein at least one of the active agents is in slow release form, is provided. A method for treating diabetes in a patient in need thereof including administering an anti-diabetic combination comprising a sodium-dependent glucose transporter (SGLT2) inhibitor and a biguanide, wherein at least one of the active agents is in slow release form, is also provided. | 02-16-2012 |
20120041070 | METHODS OF TREATING CANCER HAVING AN ABERRANT EGFR OR KRAS GENOTYPE - The invention relates to the treating cancer having an aberrant EGFR or KRAS genotype, with an AMPK activator, as well as related methods, compounds and compositions. | 02-16-2012 |
20120077879 | Process for making compositions with poorly compressible therapeutic compounds - A process for preparing solid dosage forms that contain poorly compressible therapeutic compound. The process, for example, provides for the inventive use of an extruder, especially a twin screw extruder, to melt granulate a therapeutic compound(s) with a granulation excipient. | 03-29-2012 |
20120083534 | OPHTHALMIC AND CONTACT LENS SOLUTION - An ophthalmic solution comprising a polyethoxylated glyceride in the range of 0.001 to about 10 percent by weight and a buffer agent. These solutions impart surprising comfort and wearability to contact lenses. At the same time the solutions provide good preservative capacity and do not increase protein deposit. | 04-05-2012 |
20120101166 | COMPOSITION AND METHOD FOR IRRIGATION OF A PREPARED DENTAL ROOT CANAL - Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediamine tetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection. | 04-26-2012 |
20120122991 | METHOD FOR TREATING CANCER BY INCREASING AMP-ACTIVATED KINASE ACTIVITY - The invention relates to modulation of LKB1 or AMP kinase protein activity for treating disorders including diabetes and cancer. The invention also relates to screening for agents that modulate the activity of LKB1 or AMP kinase protein, which are useful in the treatment of diabetes and cancer, as well as preparing compounds for treatment of diabetes and cancer. | 05-17-2012 |
20120157540 | Disinfectant and Sanitizer Formulations - The present invention relates to disinfectant formulations containing: (i) an antimicrobial active agent selected from the group consisting of biguanides, monoguanides, and combinations thereof; (ii) a compound selected from the group consisting of a dialkyldimethyl ammonium salt, an alkyldimethylbenzyl ammonium salt, an alkyldimethyl(ethylbenzyl) ammonium salt, and combinations thereof wherein the formulation is free of sequestrants. The total amount of the component (i) and the component (ii) is from about 500 ppm to about 1000 ppm based on the weight of the disinfectant formulation, and the component (i) and the component (ii) are present in a range of weight ratios between about 1:1 and about 1:10. | 06-21-2012 |
20120172451 | CLEANING LIQUID - The present invention relates to a cleaning fluid, in particular a cleaning fluid for cleaning surfaces. | 07-05-2012 |
20120184624 | Treatment of Alzheimer's Disease - The present invention relates to a method of treating and/or preventing Alzheimer's disease and/or other tauopathies. | 07-19-2012 |
20120202888 | BIOMARKERS OF PROSTATE CANCER AND PREDICTING MORTALITY - Measurement of circulating C-peptide levels is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of fatal prostate cancer. | 08-09-2012 |
20120220664 | USE OF METFORMIN IN CANCER TREATMENT AND PREVENTION - Disclosed herein is a method for treating a tumor in a subject in need thereof comprising administering an enhancing amount of metformin and a reduced amount of one or more chemotherapeutic agents. One example of an enhancing amount of metformin is about 250 mg/day. Also disclosed is a Untreated method for preventing cancer or delaying the recurrence of cancer in a subject comprising administering an effective amount of metformin to the subject. In one example of such a method, the amount of metformin is about 75 mg/day. Also disclosed is a composition comprising an enhancing amount of metformin, and a reduced amount of one or more chemotherapeutic agents and a pharmaceutically acceptable carrier. Kits comprising metformin and one or more chemotherapeutic agents are also disclosed. | 08-30-2012 |
20120232156 | CONTROLLED RELEASE DOSAGE FORMS - The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups. | 09-13-2012 |
20120238635 | Antiseptic Solution of Di(4-Chloro-Phenyldiguanido) Compound and Process Therefor - The present invention relates to a stable antiseptic solution comprising: a di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof, wherein said di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof is a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to a process for preparing said antiseptic solution. | 09-20-2012 |
20120283332 | TRANSDERMAL DELIVERY OF METFORMIN - Provided is a transdermal metformin that is an effective alternative treatment modality in patients with insulin resistance. Transdermal metformin can be used in conditions where oral metformin is indicated such as Type 2 diabetes mellitus, pre-diabetes, polycystic ovarian syndrome, and other known diabetes associated disorders. One advantage of using transdermal metformin is its ability to bypass the gastrointestinal system. This allows the drug to not have the gastrointestinal side-effects associated with oral metformin. A surprising advantage of using transdermal metformin in accordance with this disclosure is a 90% decrease in dosage from the oral preparation. | 11-08-2012 |
20120283333 | Ophthalmic Compositions with an Amphoteric Surfactant, Hyaluronic Acid and Polyquaternium-1 - Ophthalmic compositions that comprise 0.5 ppm to 15 ppm α-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-Ω-tris(2-hydroxyethyl) ammonium chloride; 0.005 wt. % to 0.05 wt. % hyaluronic acid; citrate, citric acid or a mixture thereof; and 0.01 wt. % to 0.8 wt. % of an amphoteric surfactant of general formula I | 11-08-2012 |
20130059916 | BIGUANIDE COMPOUNDS AND ITS USE FOR TREATING CANCER - The invention relates to a compound of formula (I), wherein the radicals R | 03-07-2013 |
20130065965 | DI(4-CHLORO-PHENYLDIGUANIDO) DERIVATIVE WHICH IS FREE OF POTENTIAL GENOTOXICITY AND A PROCESS FOR REDUCING THE RESIDUAL AMOUNT OF P-CHLOROANILINE IN SAID DI(4-CHLORO-PHENYLDIGUANIDO) DERIVATIVE - The invention relates to a process for reducing the residual amount of p-chloroaniline in chlorhexidine. Also, the invention relates to a process for preparing chlorhexidine, or a pharmaceutically acceptable salt thereof, which is free of potential genotoxicity. In addition, the invention refers to the said chlorhexidine, or a pharmaceutically acceptable salt thereof, which is free of potential genotoxicity. Further, the invention relates to an analytical HPLC method for the determination of potentially genotoxic impurities in samples of chlorhexidine, or of a pharmaceutically acceptable salt thereof. The invention also relates to stabilized chlorhexidine digluconate salt free of potential genotoxicity in aqueous solution, and to a method for stabilizing chlorhexidine digluconate salt free of potential genotoxicity in aqueous solution. | 03-14-2013 |
20130072566 | ANTIMICROBIAL COMPOSITIONS - Antimicrobial compositions are provided that include a hydroalcoholic solvent system comprising a lower C | 03-21-2013 |
20130150451 | BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME - An antimicrobial composition with synergistic biocidal activity is described which comprises at least one antimicrobial polymeric biguanide and at least one antimicrobial vicinal diol, said vicinal diol comprises at least one monoalkyl glycol, monoalkyl glycerol, or monoacyl glycerol, to diminish or eliminate biofilm communities. Such synergistic interaction is effective in wound treatment, particularly for chronic wounds, burns and battlefield-induced wounds, as well as for disinfecting non-biological surfaces. The antimicrobial composition can also be prepared as viscous solutions or as gels. The antimicrobial composition may be added to a substrate and dried, such as to a catheter, or to a foam, or to a fiber wound dressing, or coated as a viscous solution or gel upon such devices, to provide controlled release antimicrobial activity. | 06-13-2013 |
20130150452 | Antimicrobial Medical Devices Containing Chlorhexidine Free Base and Salt - The present disclosure invention relates to medical devices treated with a solution comprising one or more solvents and a combination of chlorhexidine free base and a water-soluble chlorhexidine salt in a weight/weight ratio of between about 1:1 to about 1:5, preferably about 1:1. | 06-13-2013 |
20130165524 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME - The present invention relates to the administration of compositions comprising an antiestrogen, preferably trans-clomiphene, for treating metabolic syndrome in a subject. The invention is also directed to methods for reducing fasting glucose levels in a subject by administering a composition comprising an antiestrogen, preferably trans-clomiphene. | 06-27-2013 |
20130217778 | METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF SKELETAL MUSCLE FUNCTION IN A MAMMAL - The present invention is directed to the treatment of muscular dysfunction or increasing muscle strength and/or decreasing muscle fatigue in a subject using a composition that includes a biguanide or a pharmaceutically acceptable salt thereof, e.g., at a low dosage. | 08-22-2013 |
20130231394 | ANTIMICROBIAL WOUND DRESSING - The invention relates to a wound dressing comprising a polymer substrate and a compound comprising a) at least one antimicrobial active agent and b) an agent that reduces the cytotoxicity, comprising an oil-in-water emulsion that additionally has one or more alkanediol(s) and/or one or more glyceryl ether(s). | 09-05-2013 |
20130237605 | COMPOSITIONS, METHODS, AND KITS FOR REGULATING ENERGY METABOLISM - The present invention provides for compositions, methods and kits for regulating energy metabolism. In one aspect, the invention provides for compositions that comprise a combination of (a) branched chain amino acids, such as leucine, and (b) vitamin B6, or any precursors or metabolites of (a) or (b). These combinations may be synergistic and/or effective for reducing weight or adipose volume. In another aspect, the invention provides for methods of regulating energy metabolism by the administration of one or more compositions comprising branched chain amino acids and vitamin B6. The invention also provides for kits comprising compositions of branched chain amino acids and vitamin B6 packaged in an oral dose form with usage instructions. | 09-12-2013 |
20130261190 | Ophthalmic Compositions with Biguanide and PEG-Glycerol Esters - Ophthalmic compositions comprising 0.5 ppm to 5 ppm of alexidine, and 0.005 wt. % to 0.3 wt. % of glycereth-18-ethylhexanoate. The invention is also directed to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone, hydrogel contact lenses. | 10-03-2013 |
20130303622 | AQUEOUS ANTI-MICROBIAL SOLUTION CONTAINING CHLORHEXIDINE DIGLUCONATE AND TARTARIC ACID, METHOD FOR PREPARING SAME, AND ANTI-MICROBIAL ORTHODONTIC CEMENT - The present invention deals with a method for the preparation of an antimicrobial aqueous solution containing chlorhexidine digluconate and tartaric acid for use with dental/orthodontic glass ionomer cement, and an antimicrobial aqueous solution substantially improved by the inclusion of chlorhexidine digluconate up to 18% and tartaric acid up to 11%. | 11-14-2013 |
20140045947 | Methods for Maintaining or Improving Health, Well-Being and/or a Physiological Function in a Subject - The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. | 02-13-2014 |
20140057987 | Disinfectant Spray with Indicator - Compositions are provided that comprise a disinfectant, a pH indicator dye, and an alkaline substance. The pH indicator dye expresses a color when initially sprayed, but loses or changes color once sprayed. The compositions may be used to disinfect surfaces, and the pH indicator dye indicates what surface has been disinfected and ensures that a sufficient period of time has passed to disinfect the surface. Dispensing systems that are not fully air tight are provided for containing and dispensing the composition. | 02-27-2014 |
20140073699 | Combination Therapies for the Treatment of Obesity - Described are pharmaceutical compositions comprising phentermine, metformin, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of phentermine and metformin. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 03-13-2014 |
20140107214 | COMPOSITION AND METHOD FOR IRRIGATION OF A PREPARED DENTAL ROOT CANAL - Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediaminetetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection. | 04-17-2014 |
20140121280 | METHODS OF TREATMENT OF THE DENTAL PULP AND FILLING ROOT CANALS USING WATER-BASED MATERIAL - A dental composition comprising: a) about 1 to about 80% by weight of particulate material including: (i) calcium silicate, calcium aluminate, tetracalcium aluminoferrite, calcium phosphate, calcium sulfate, silica, alumina, calcium oxide, calcium hydroxide, or mixtures thereof; and b) about 1 to about 50% by weight liquid carrier including: (i) water-soluble polymer, (ii) surfactant, the surfactant is selected from the group consisting of alkyl sulfates, alkyl ether sulfates, and sarcosinates, and mixtures thereof; and (iii) water; wherein the particulate and liquid carrier being mixed together to form a hydrate gel material that can harden. | 05-01-2014 |
20140171512 | FOOD CONTACT DISINFECTING/SANITIZING FORMULATION AND WIPE - Disclosed is a sanitizing/disinfecting composition containing a quaternary ammonium compound and a polybiguanide. The composition is a food contact safe composition which does not need rinsing after being applied to a substrate. The composition may be saturated into a wipe. | 06-19-2014 |
20140235727 | ANTIMICROBIAL HYDROGEL POLYMERS - The present invention relates generally to antimicrobial hydrogel polymers, and dressings comprising one or more hydrogel-forming hydrophilic polymers, where the hydrogels and dressings further comprise one or more antimicrobial agents that are released from the hydrogel in a controlled manner. The hydrogels and dressings may be used for medical, veterinary, and/or cosmetic applications. The dressings may be applied, for example, as wound dressings, surgical dressings, and percutaneous site dressings. In certain aspects of the invention, the dressings may be beneficially used in methods of accelerating wound healing, preventing and/or reducing the incidence of wound infection, and reducing scarring associated with wounds. | 08-21-2014 |
20140243417 | Composition with Sustained Antimicrobial Activity - Disclosed herein are compositions comprising benzyl alcohol, one or more cationic antimicrobial agent, and one or more emollient, the combination of which results in persistent antimicrobial activity after application to the skin. The compositions optionally further comprise an organic acid and/or a zinc salt, such as zinc gluconate, as an anti-irritant. | 08-28-2014 |
20140256820 | THERAPEUTIC AGENT FOR BLOOD-BRAIN BARRIER DISRUPTION SYNDROME - A medicinal agent or a pharmaceutical composition, each of which comprises a biguanides agent or a pharmaceutically acceptable salt thereof as an active ingredient, and which can potentiate blood-brain barrier functions including tight junction capability and transcellular transport capability of a brain capillary endothelial cell and therefore can treat blood-brain barrier dysfunction syndrome. | 09-11-2014 |
20140275274 | SYNERGISTIC OPHTHALMIC COMPOSITIONS FOR DISINFECTING CONTACT LENSES - Compositions and methods for disinfecting contact lenses using the compositions are disclosed. The compositions include a combination of alexidine and chlorhexidine, which surprisingly causes the composition to exhibit synergistic antimicrobial activity against | 09-18-2014 |
20140275275 | Chlorhexadine Antiseptic - A composition comprising a mixture of chlorohexidine, a surfactant, and a cationic quaternary ammonium compound is suitable for use as an antiseptic and is surprisingly effective against difficult-to-kill organisms such as | 09-18-2014 |
20150031772 | ADJUSTABLE BIOACTIVE AGENT DISPERSION WITHIN A POLYMERIC COATING - A coating comprised of a polymeric material and a bioactive agent where the properties of the casting solvent dictate the dispersion of the embedding bioactive agent. In preferred embodiments, controlled release of the bioactive agent is achieved by homogeneous dispersion of the bioactive agent within the coating. A further aspect of the invention is directed to formulations where the heterogeneous dispersion of the bioactive agent provides an initial rapid release of the bioactive agent. Methodology for production of coating formulations of the desired properties and the application of the coating to an article are also described. | 01-29-2015 |
20150038589 | Nutritional Product Comprising a Biguanide - The present invention relates to a nutritional product comprising a biguanide in a concentration of 20 to 1600 mg per 100 g, based on total weight of the nutritional product, the nutritional product further comprising at least one dietary component selected from the group of (i) digestible carbohydrates, (ii) amino acid sources, such as proteins, peptides, free amino acids including salts of free amino acids, (iii) lipids, and (iv) dietary fibre. The invention further relates to a nutritional product comprising a biguanide for use in a prophylactic or therapeutic treatment of an aging-associated disorder. | 02-05-2015 |
20150065578 | Compositions and Methods for Treating Metabolic Disorders - Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine. | 03-05-2015 |
20150073057 | COMPOSITION AND METHOD FOR TREATMENT OF DIABETES - The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of metformin to the colon by bypassing the upper digestive tract. | 03-12-2015 |
20150087716 | ANTIMICROBIAL MEDICAL DEVICES CONTAINING CHLORHEXIDINE FREE BASE AND SALT - The present disclosure invention relates to medical devices treated with a solution comprising one or more solvents and a combination of chlorhexidine free base and a water-soluble chlorhexidine salt in a weight/weight ratio of between about 1:1 to about 1:5, preferably about 1:1. | 03-26-2015 |
20150087717 | ANTIMICROBIAL COMPOSITIONS CONTAINING CATIONIC ACTIVE INGREDIENTS AND QUATERNARY SUGAR DERIVED SURFACTANTS - The antimicrobial composition of the present invention comprises a cationic active ingredient, a quaternized sugar-derived surfactant, and an optional foam boosting surfactant. These formulations have a high cidal activity in a short amount of time and provide stable copious foam. The formulations of the present invention also exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method. | 03-26-2015 |
20150105472 | ANTIMICROBIAL COMPOSITION - The invention relates to an antimicrobial composition comprising chlorhexidine and pentane-1,5-diol. Such a composition may be used to combat microorganisms. | 04-16-2015 |
20150290100 | ANTIMICROBIAL COMPOSITIONS CONTAINING CATIONIC ACTIVE INGREDIENTS AND QUATERNARY SUGAR DERIVED SURFACTANTS - The antimicrobial composition of the present invention comprises a cationic active ingredient, a quaternized sugar-derived surfactant, and an optional foam boosting surfactant. The present antimicrobial compositions are free of the antimicrobial agent triclosan (i.e., 2,4,4′-trichloro-2′hydroxy-diphenylether), have a high cidal activity in a short amount of time, provide stable copious foam and exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method. | 10-15-2015 |
20150328360 | CHLORHEXIDINE GLUCONATE COMPOSITIONS, RESIN SYSTEMS AND ARTICLES - Compositions containing chlorhexidine gluconate solubilized in hydrophobic vehicles are described. Resin systems containing such chlorhexidine gluconate compositions, including adhesives and articles incorporating such resin systems, including medical articles such as drapes are also described. | 11-19-2015 |
20150342181 | IMPROVED ANTIMICROBIAL COMPOSITION - Antiseptic hand rub composition comprising at least 0.2% w/w of isopropyl myristate, free from other derivatives of myristic acid. Phenoxyethanol is preferably present in the composition at a concentration of 1% by wt or less. A glycol may also be present, such as dipropylene glycol if the composition is an ethanol based hand rub gel or propylene glycol if the composition is in the form of an emulsion or dispersion. Additional biocides such as triclosan and chlorhexidine gluconate may be included. | 12-03-2015 |
20150367021 | Antimicrobial Adhesives Having Improved Properties - Adhesive compositions exhibiting antimicrobial properties, good stability, long shelf lives and enhanced release of antimicrobial agents are described. In certain versions, the compositions also exhibit relatively high fluid handling capacities. The adhesive compositions inhibit microbial growth by more than 2 log after 24 hours contact and particularly more than 3.5 log after 6 hours contact. Also described are various medical articles using such adhesives and related methods. | 12-24-2015 |
20160030367 | Methods and Compositions for Preventing Metastasis and for Improving the Survival Time - The invention relates to an AMPK activator (such as for instance metformin) for use in preventing metastasis in a patient suffering from a cancer, wherein said patient has a non-mutated p53 gene or lacks a mutant form of the p53 protein. The invention also relates to an AMPK activator for use in improving the survival time of a patient suffering from a cancer, wherein said patient has a non-mutated p53 gene or lacks a mutant form of the p53 protein. | 02-04-2016 |
20160068651 | REACTION MIXTURE, POROUS PARTICLES AND METHODS OF MAKING - Porous polymeric particles are provided that can be hydrophilic or hydrophobic. The porous polymeric particles can be used for the storage and delivery of various active agents or for moisture management. Reaction mixtures for forming the porous polymeric particles, methods of making the porous polymeric particles, and articles containing the porous polymeric particles are also provided. | 03-10-2016 |
20160073636 | ANTIMICROBIAL COMPLEXES - The invention generally relates to certain antimicrobial, antibacterial, antifungal or antiviral compounds. More particularly, the invention relates to certain antimicrobial antibacterial, antifungal and/or antiviral compounds, their syntheses and compositions, and methods of use thereof. | 03-17-2016 |
20160081894 | Invisible Antimicrobial Glove and Hand Antiseptic - An alcohol based hand surgical scrub, which includes cationic anti-microbial agent preservatives, cationic polymer film-forming agents and a skin emollient, and provides a long term residual, anti-microbial “invisible glove” on the skin. The composition provides an immediate reduction in bacterial microbes. The polymer system creates an invisible film on the skin following solvent evaporation. This invisible film provides a lasting anti-microbial barrier on the skin which acts to prevent microbial growth. | 03-24-2016 |
20160160267 | COMPOSITION FOR EVALUATING OR PREDICTING PATIENTS THERAPEUTIC RESPONSE TO METHORMIN - The present invention relates to a biomarker for evaluating or predicting response of a patient to metformin, and use thereof. The present invention relates to a composition and a kit for evaluating or predicting therapeutic response of a patient to metformin, comprising an agent capable of detecting one or more microorganisms selected from the group consisting of | 06-09-2016 |
20160174562 | OPHTHALMIC CONTACT LENS SOLUTIONS CONTAINING FORMS OF VITAMIN B | 06-23-2016 |
20160199526 | OPHTHALMIC SOLUTION | 07-14-2016 |